Management of Peanut Allergy

This activity is available for free to members of NASP. Visit the top section of for details.


A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities

Activity Description

This presentation discusses the prevalence, pathophysiology, and epidemiology for IgE-mediated food allergy with a special focus on peanut allergy. We will discuss the clinical features, diagnostics, and management of food allergy. We will discuss how oral immunotherapy can induce tolerance and the mechanism of tolerance induction. Special focus will be on the new FDA-approved peanut oral immunotherapy product, Palforzia, and the processes and procedures for prescribers, healthcare settings, and pharmacists to be aware of to prescribe and dispense Palforzia. Finally, we will review other potential future therapies for management of peanut allergy.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:

  • Discuss the prevalence, pathophysiology, immunological, and molecular basis of peanut allergy.
  • Review the clinical history, presentation, and current management of food allergy and anaphylaxis.
  • Explain oral immunotherapy (OIT), the mechanism of action by which tolerance to food allergens can be developed, and current therapies.
  • Identify potential future therapies for management of peanut/nut allergy.


Amanda Michaud, MMS, PA-C, DMSc candidate
Arizona Asthma and Allergy Institute
Scottsdale, Arizona


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Amanda Michaud does not have any relevant financial and/or commercial relationships to disclose.

CE Accreditation

Release Date: December 11, 2020
Expiration Date: December 11, 2023


This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-527-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


No external support has been received for this activity.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.